scispace - formally typeset
S

Sanjeev Saksena

Researcher at Atlantic Health System

Publications -  174
Citations -  6606

Sanjeev Saksena is an academic researcher from Atlantic Health System. The author has contributed to research in topics: Atrial fibrillation & Cardioversion. The author has an hindex of 44, co-authored 169 publications receiving 6463 citations. Previous affiliations of Sanjeev Saksena include University of Minnesota & Newark Beth Israel Medical Center.

Papers
More filters
Journal ArticleDOI

Two-dimensional echocardiographic studies during sustained ventricular tachycardia.

TL;DR: 2DE is feasible during clinical electrophysiologic studies for sustained VT and may be a useful adjunct in studying the physiologic impact of VT; WMA generally worsens during VT but can appear less evident due to declining systolic function in adjacent viable myocardium.
Journal ArticleDOI

Low-Energy Endocardial Defibrillation Using Dual, Triple, and Quadruple Electrode Systems

TL;DR: The feasibility of achieving both universal application of nonthoracotomy leads and low (< or = 15 J) defibrillation energy requirements by optimizing lead system configuration for use with low-output biphasic shock pulse generators was examined and reduction in maximum pulse generator output to < or =25 J using these electrode configurations with bidirectional shocks is feasible and maintains an adequate safety margin.
Journal ArticleDOI

Right and left atrial activation during external direct-current cardioversion shocks delivered for termination of atrial fibrillation in humans.

TL;DR: It is concluded that termination of AF with external cardioversion shocks is associated with the widespread extinction of regional atrial wave fronts and with a temporary slowing of atrial activation at all regions except at the interatrial septum and emergence of organized and/or rapidly propagating wave fronts.
Journal ArticleDOI

Surgical ablation of tachyarrhythmias: reflections for the third decade.

TL;DR: As surgical therapy for tachycardias enters its third decade, it competes with pharmacologic agents, catheter ablation methods and antitachycardia devices as a therapeutic option for patients with SVT and VT.